FDA approves new therapy option for lung cancer patients who develop resistance to early generation EGFR inhibitors

Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common “classical” …